Doctors at the University of Minnesota are the first in the country to use a breakthrough brain cancer treatment.
It sounds like science fiction, but doctors at University of Minnesota Health are the first in the country to offer an implantable form of radiation to target brain cancer.
The implant is called GammaTile Therapy and Linda Tinega was the first patient in Minnesota to receive it.
“Each tile, has four, radioactive seeds on it,” said Tinega, who had five GammaTiles implanted during surgery to remove a cancerous brain tumor two weeks ago. “Health wise and stuff, it’s not even like they’re in there. I can’t feel them.”
Read the full story at https://www.kare11.com/article/news/new-brain-cancer-treatment-at-the-university-of-minnesota/89-d0b5f5d4-fb9f-4fc4-8f70-802e12858399
University of Minnesota First in U.S. to Offer New Targeted Therapy for Recurrent Brain Tumors
GT MedTech’s Innovative GammaTile Therapy Is Shown to Slow Brain Tumor Progression, Designed to Improve Patient and Caregiver Quality of Life
February 14, 2019 08:22 AM Eastern Standard Time
MINNEAPOLIS & TEMPE, Ariz.–(BUSINESS WIRE)–University of Minnesota Health (M Health) is the first health system in the United States to begin offering GammaTile Therapy™, a new approach to treating recurrent brain tumors. GammaTile Therapy is an FDA-cleared, surgically targeted radiation therapy (STaRT™) that is designed to delay tumor regrowth for patients with brain tumors. The first patient was treated by University of Minnesota Physician, Clark C. Chen, M.D., Ph.D., head of the Department of Neurosurgery at the University of Minnesota Medical School.
“Moreover, the University of Minnesota Medical School’s Department of Neurosurgery has a long-standing history of contribution in radio-biologics. To be the first institution in the U.S. to offer the GammaTile Therapy is particularly satisfying in this context.”
Aggressive brain tumors tend to be resistant to current treatments and nearly always recur. Outcomes for patients with brain tumors have improved very little over the past 30 years. GammaTile is FDA-cleared for patients with recurrent brain tumors. GammaTile consists of a bioresorbable, conformable 3D-collagen tile embedded with a Cesium radiation source. GammaTile is placed at the time of surgery so that it immediately begins to target residual tumor cells with radiation while limiting the impact on healthy brain tissue.
“I am optimistic that GammaTile will impact the clinical outcome for our brain tumor patients, particularly when combined with appropriate medical therapy,” explained Chen.
GammaTile Therapy offers some advantages over other treatments for patients undergoing surgery for recurrent brain tumors. A course of External Beam Radiation Therapy (EBRT), for example, requires daily treatments for up to six weeks; in contrast, patients treated with GammaTile Therapy require no additional trips to the hospital or clinic. Additionally, many patients may not be candidates for EBRT at the time of tumor recurrence because the risk of additional EBRT outweighs the potential benefits. Finally, those patients who may be candidates for EBRT typically have to wait four weeks or more for surgical wound healing before beginning treatment, allowing residual, microscopic tumors to grow during this waiting period.
Dr. Chen has conducted research that supports the efficacy of radiation treatment immediately after resection. Published in the Journal of Neuro-Oncology, Chen’s study showed that patients with glioblastoma, the most common form of primary brain cancer in adults who received immediate postoperative radiation exhibited improved survival relative to those who did not.
“I am pleased to be able to offer a more targeted radiation therapy to my patients,” said Kathryn E. Dusenbery, M.D., head of the Department of Radiation Oncology at the University of Minnesota Medical School. “With GammaTile, we apply radiation therapy exactly where it is needed, without harming surrounding tissue, and patients do not need to come back for ongoing radiation treatments. In addition, this new targeted approach may help reduce the burden of ongoing radiation treatment and help my patients and their caregivers experience a better quality of life.”
Additional data supporting the efficacy and safety profile of the therapy for patients with recurrent, previously treated meningiomas were published last month in the Journal of Neurosurgery (JNS), the official journal of the American Association of Neurological Surgeons. Clinical data from other types of tumors will be presented at the AANS Annual Scientific Meeting in April.
“We are honored to be working with the brain tumor specialists at the University of Minnesota – given the health system’s deep expertise and leadership in brain tumor treatment and neurosurgery – to deploy GammaTile Therapy for the purpose of improving the lives of patients with brain tumors,” said Matt Likens, president and CEO of GT MedTech. “We are excited to begin expanding the availability of GammaTile Therapy to other leading brain tumor treatment centers across the U.S.”
About University of Minnesota Health
University of Minnesota Health represents a collaboration between University of Minnesota Physicians and University of Minnesota Medical Center. Working together, we provide exceptional care in a wide range of specialties at our hospitals, clinics and in community-based facilities throughout the region. Visit: www.mhealth.org.
About GT Medical Technologies, Inc.
Driven to overcome the limitations of current treatments for recurrent brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with recurrent brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors in July 2018 and has an established CMS code for Medicare reimbursement. Extensive clinical expertise informed the design of GammaTile Therapy, and deep medical device experience guides the company. The company is headquartered in Tempe, Arizona. For more information, visit https://www.gtmedtech.com/.
About the University of Minnesota Medical School
The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Visit med.umn.edu to learn how the University of Minnesota is innovating all aspects of medicine.
Contacts
Jana Chow
Health+Commerce
925-324-9846
jana@healthandcommerce.com
Krystle Barbour, Media Relations Manager
Office of Communications – Medical School
University of Minnesota | med.umn.edu
612-626-2767
kbarbour@umn.edu